• Mashup Score: 19

    Results for “plenary session” Results The 2025 AS CO Annual Meeting is funded through Conquer Cancer®, the ASCO Foundation, by these sponsorship donors. AbbVie, Inc. Bristol Myers Squibb Daiichi Sankyo, Inc.

    Tweet Tweets with this article
    • RT @drenriquegrande: #ASCO25 abstracts titlkes are out!!!!! https://t.co/ybAeFhH4He Much Looking forward to seeing the exciting new data in…

  • Mashup Score: 5

    Presenter: Rui-Hua Xu, MD, PhD Presenter: Aaron Elliott Lisberg, MD Presenter: Silver Alkhafaji, BS Discussant: Emil Lou, MD, PhD Discussant: Lillian L. Siu, MD, FASCO, FRCPC Presenter: Jaume Capdevila, MD, PhD Presenter: Tadayoshi Hashimoto, MD, PhD Presenter: Thorvardur Ragnar Halfdanarson, MD Discussant: Heloisa P. Soares,

    Tweet Tweets with this article
    • For easy access to today's announced list for the #ASCO25 Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology Oral Abstract Session: https://t.co/Fd2SyUfPo0 https://t.co/0k0hAn6Bhn

  • Mashup Score: 19

    Results for “plenary session” Results The 2025 AS CO Annual Meeting is funded through Conquer Cancer®, the ASCO Foundation, by these sponsorship donors. AbbVie, Inc. Bristol Myers Squibb Daiichi Sankyo, Inc.

    Tweet Tweets with this article
    • RT @drenriquegrande: #ASCO25 abstracts titlkes are out!!!!! https://t.co/ybAeFhH4He Much Looking forward to seeing the exciting new data in…

  • Mashup Score: 19

    Results for “plenary session” Results The 2025 AS CO Annual Meeting is funded through Conquer Cancer®, the ASCO Foundation, by these sponsorship donors. AbbVie, Inc. Bristol Myers Squibb Daiichi Sankyo, Inc.

    Tweet Tweets with this article
    • RT @drenriquegrande: #ASCO25 abstracts titlkes are out!!!!! https://t.co/ybAeFhH4He Much Looking forward to seeing the exciting new data in…

  • Mashup Score: 52

    The field of rare cancer research is rapidly transforming, marked by significant progress in clinical trials and treatment strategies. Rare cancers, as defined by the National Cancer Institute, occur in fewer than 150 cases per million people each year, …

    Tweet Tweets with this article
    • Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras | American Society of Clinical Oncology Educational Book @ASCO Ed Book #ASCO25 https://t.co/BqWIGpeh7u

  • Mashup Score: 31

    Therapeutic advances have resulted in a growing population of childhood cancer survivors. Unfortunately, this success comes at a price. A substantial proportion of the survivors develop life-threatening chronic health conditions such as subsequent …

    Tweet Tweets with this article
    • Redefining Survivorship in Pediatric Oncology: A Fresh Look at a Long-Term Problem | American Society of Clinical Oncology Educational Book https://t.co/OAYBK9W0dQ @ASCO #ASCO25 https://t.co/Cp7OJB6WZu

  • Mashup Score: 29

    The integration of targeted therapies into neuro-oncology is revolutionizing the management of primary CNS malignancies. Advances in sequencing technologies and the incorporation of molecular alterations into CNS tumor classification have led to more …Targeted therapy in neuro-oncology practice, encompassing recent approvals and ongoing trials, focuses on addressing key clinical and research challenges.

    Tweet Tweets with this article
    • Incorporating Targeted Therapy Into Neuro-Oncology Practice | American Society of Clinical Oncology Educational Book https://t.co/fjYeivhlpI @ASCO #ASCO25 https://t.co/95R7SbuaBT